Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis

INTRODUCTION: Cerebral atrophy is a compound measure of the neurodegenerative component of multiple sclerosis (MS) and a conceivable outcome measure for clinical trials monitoring the effect of neuroprotective agents. In this study, we evaluate the rate of cerebral atrophy in a 6-month period, inves...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Elskamp, I. J., Boden, B., Dattola, V., Knol, D. L., Filippi, M., Kappos, L., Fazekas, F., Wagner, K., Pohl, C., Sandbrink, R., Polman, C. H., Uitdehaag, B. M. J., Barkhof, F.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Diagnostic Neuroradiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938443/
https://www.ncbi.nlm.nih.gov/pubmed/20049424
http://dx.doi.org/10.1007/s00234-009-0645-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938443/
https://www.ncbi.nlm.nih.gov/pubmed/20049424
http://dx.doi.org/10.1007/s00234-009-0645-1

Ejemplares similares